The COVID-19 Resource Centre, established by Elsevier in January 2020, provides free information in English and Mandarin on the novel coronavirus. The centre is hosted on Elsevier Connect and grants permission for all COVID-19-related research to be immediately available in PubMed Central and other public repositories, with unrestricted reuse and analysis, provided the original source is acknowledged. The article also discusses the potential of combining antiviral and anti-inflammatory treatments for COVID-19, highlighting the use of baricitinib, a JAK inhibitor, as a promising candidate due to its high affinity for AAK1, its anti-inflammatory properties, and favorable pharmacokinetic characteristics. The authors suggest that baricitinib could be effective in reducing viral infectivity and the host inflammatory response, and its potential for combination therapy with other antivirals is also explored.The COVID-19 Resource Centre, established by Elsevier in January 2020, provides free information in English and Mandarin on the novel coronavirus. The centre is hosted on Elsevier Connect and grants permission for all COVID-19-related research to be immediately available in PubMed Central and other public repositories, with unrestricted reuse and analysis, provided the original source is acknowledged. The article also discusses the potential of combining antiviral and anti-inflammatory treatments for COVID-19, highlighting the use of baricitinib, a JAK inhibitor, as a promising candidate due to its high affinity for AAK1, its anti-inflammatory properties, and favorable pharmacokinetic characteristics. The authors suggest that baricitinib could be effective in reducing viral infectivity and the host inflammatory response, and its potential for combination therapy with other antivirals is also explored.